|  | Perlecan Negative | Perlecan Positive |  |
---|---|---|---|---|
Histology | Tumor | 170 | 203 | Â |
 | Normal | 211 | 31 | p < 0.00005 |
 | Tumor | 170 | 203 |  |
 | HGPIN | 46 | 7 | p < 0.00005 |
Clinical Stage | cT2 | 11 | 12 | Â |
 | cT3/4 | 2 | 3 | N.S. |
Tumor Grade | Gleason 6 | 26 | 5 | Â |
 | Gleason 7,8,9 | 38 | 23 | p = 0.0335 |
Pathologic Stage | pT1-pT2 | 35 | 17 | Â |
 | pT3 | 29 | 11 | N.S. |
Nodal Status | pN0 | 18 | 23 | Â |
 | pN1 | 0 | 1 | N.S. |
Outcomes | PSA Recurrence | 4 | 5 | Â |
 | No PSA Recurrence | 13 | 22 | N.S. |
Vital Status | Alive | 26 | 36 | Â |
 | Dead | 2 | 5 | N.S. |
Perlecan Expression in Metastasis | ||||
Metastatic Site | Â | Perlecan Negative | Perlecan Positive | P value vs. Prostate |
Primary Tumor (Prostate) | Â | 3 | 24 | Â |
Lymph Node | Â | 8 | 9 | p = 0.0073 |
Soft Tissue | Â | 15 | 18 | p = 0.0039 |
Liver | Â | 5 | 23 | p = 0.4781 |
Lung | Â | 3 | 24 | p = 1.000 |
Association of Ki-67 (PCNA) Staining with Perlecan Staining | ||||
Sample Staining | Â | Number of Samples | Mean % of Ki-67 positivity | Two-tailed ANOVA |
Perlecan positive | Â | 143 | 6.715278 | p = 0.0478 |
Perlecan negative | Â | 214 | 5.028571 | Â |